Blog
Featured post
Truveta Data now includes more than 120 million de-identified patients
Truveta has also partnered with more than 100 organizations across life sciences, healthcare, public health, academic research organizations, and others to use regulatory-grade EHR data enabling scientifically rigorous research.
Real-time monitoring of respiratory virus-associated hospitalizations: Trends through November 2024
Between the last week of October and the last week of November, there was a 58.8% increase in respiratory virus-associated hospitalizations. For infants and children under the...
Exploring first-time GLP-1 prescriptions and new comorbidity diagnoses
In partnership with Reuters, Truveta Research explored the percentage of patients who received a first-time diagnosis of type 2 diabetes, cardiovascular disease, or sleep apnea...
Adderall shortage: Exploring first-time Adderall prescriptions and fill rates
First-time amphetamine/dextroamphetamine prescription rates remained stable overall, but increased significantly for people 30-44, 45-64, and 65+ years of age. The percentage of...
Adderall shortage: Exploring first-time ADHD diagnosis rates
The rate of first-time ADHD diagnoses has increased since 2021. The largest increases in first-time ADHD diagnosis rates were seen in the 30-44-year-old and 45-64-year-old age...
Combating respiratory viruses with EHR data: Key use cases for life sciences and public health
“For the first time in the history of health, we have enough data at scale to dramatically advance innovation in healthcare” – Michael Slubowski, president & CEO, Trinity...
An AI platform that supports adjacencies
In the final article in this series, I will share some thoughts on meeting the following challenge: How to rapidly support new AI scenarios and adjacencies through reuse and...
A year later: New GLP-1 clinical trial results validate Truveta’s real-world data study
New results released this week from the SURMOUNT-5 clinical trial comparing tirzepatide (Zepbound) to semaglutide (Wegovy) are closely aligned to Truveta Research’s GLP-1...
Real-time monitoring of respiratory virus-associated hospitalizations: Trends through October 2024
RSV-associated hospitalizations increased 191.5% throughout October 2024. RSV-associated hospitalizations also increased in vulnerable populations with a 233.3% in infants and...
Truveta achieves HITRUST r2 Certification
We are excited to share that our platform Truveta Studio and Truveta Data have earned certified status by HITRUST for information security. This achievement places Truveta in an...